Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:5151 |
Name | plexiform neurofibroma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer peripheral nervous system neoplasm peripheral nerve sheath neoplasm neurofibroma plexiform neurofibroma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00030264 | Phase II | Vinblastine Methotrexate | Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas | Completed | USA | 0 |
NCT01362803 | Phase Ib/II | Selumetinib | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | Active, not recruiting | USA | 0 |
NCT02101736 | Phase II | Cabozantinib | Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) | Completed | USA | 0 |
NCT02124772 | Phase I | Trametinib Dabrafenib + Trametinib | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | Completed | USA | GBR | FRA | CAN | AUS | 0 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02407405 | Phase II | Selumetinib | MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | Active, not recruiting | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT03231306 | Phase II | Binimetinib | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI) | Active, not recruiting | USA | 0 |
NCT03326388 | Phase Ib/II | Selumetinib | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours (INSPECT) | Completed | GBR | 0 |
NCT03363217 | Phase Ib/II | Trametinib | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | Active, not recruiting | CAN | 0 |
NCT03688568 | Phase II | Imatinib | Study of Imatinib in Children With Neurofibromatosis and Airway Tumors | Withdrawn | USA | 0 |
NCT03962543 | Phase II | PD-0325901 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu) | Active, not recruiting | USA | 0 |
NCT04465643 | Phase I | Ipilimumab + Nivolumab | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Recruiting | USA | 0 |
NCT04750928 | Phase Ib/II | Abemaciclib | Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | Recruiting | USA | 0 |
NCT04924608 | Phase III | Selumetinib | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT04954001 | Phase Ib/II | FCN-159 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | Active, not recruiting | USA | ESP | 1 |
NCT05101148 | Phase I | Selumetinib | Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Toxicity of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas | Active, not recruiting | USA | POL | ESP | 1 |
NCT05309668 | Phase Ib/II | Selumetinib | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged >/=1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE) | Active, not recruiting | USA | NLD | ITA | ESP | DEU | 2 |
NCT06104488 | Phase I | RO5126766 | A Study of Avutometinib for People With Solid Tumor Cancers | Recruiting | USA | 0 |
NCT06502171 | Phase I | Cabozantinib + Selumetinib | Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas (NF113) | Not yet recruiting | USA | 0 |